A Hong Kong-based an­ti­body mak­er has filed for an IPO on the HKEX, mark­ing the first tru­ly home­grown com­pa­ny to take ad­van­tage of new rules that al­low pre-rev­enue biotechs to list on the stock ex­change.

Shawn Le­ung HK­IB

Founder and CEO Shawn Le­ung calls SinoMab an in­dus­try pi­o­neer in the re­gion, hav­ing start­ed out in 2002 with sup­port from Morn­ing­side — at a time the city’s lead­ers ap­peared more in­ter­est­ed in “ra­tio­nal­iza­tion” of Chi­nese med­i­cine. Le­ung, an Ox­ford-ed­u­cat­ed lo­cal who trained in the US first as a post­doc then at Im­munomedics, came up with his own frame­work for hu­man­iz­ing an­ti­bod­ies. That formed the ba­sis of SinoMab’s cur­rent pipeline, which com­pris­es a lead an­ti-CD22 drug, a BTK in­hibitor, and four oth­er pre­clin­i­cal mAbs.

With SM03, SinoMab is tar­get­ing some of the biggest in­di­ca­tions in im­munol­o­gy: rheuma­toid arthri­tis (PhI­II), sys­temic lu­pus ery­the­mato­sus (PhI) and Sjö­gren’s syn­drome (IND), in ad­di­tion to non-Hodgkin’s lym­phoma (PhII).

While Le­ung has kept the com­pa­ny’s head­quar­ters in Hong Kong’s Sci­ence Park, he’s al­so ex­pand­ed SinoMab’s foot­print, with an of­fice in Shen­zhen, a pro­duc­tion plant in Hainan and a sub­sidiary in Aus­tralia to fa­cil­i­tate clin­i­cal tri­als.

“In fu­ture, we ex­pect to lean more to­wards Chi­na be­cause we are in­creas­ing­ly see­ing that that is where the tal­ent, the mar­ket and the mon­ey are,” he said in a 2017 in­ter­view with Phar­ma Board­room. “As we are look­ing to po­si­tion our­selves for mar­ket ap­proval, we are cur­rent­ly in­vest­ing in a new man­u­fac­tur­ing plant in Chi­na and we need chan­nels to source the mon­ey for that. An ex­pand­ed pres­ence in Chi­na will al­so help us ex­pand our port­fo­lio and gain more col­lab­o­ra­tion, both lo­cal­ly and glob­al­ly.”

Le­ung, who’s al­so a mem­ber of the HKEX’s biotech ad­vi­so­ry board, adds that Hong Kong, nev­er­the­less, re­tains a cru­cial edge with re­gards to in­tel­lec­tu­al prop­er­ty:

This is not some­thing that com­pa­nies nec­es­sar­i­ly want to do in Chi­na; if an em­ploy­ee de­cides to leave with valu­able da­ta, the sheer phys­i­cal size and pop­u­la­tion den­si­ty of Chi­na mean that he can eas­i­ly dis­ap­pear with­out a trace. In Hong Kong, the in­fra­struc­ture is trust­wor­thy and ro­bust. The biotech com­mu­ni­ty is al­so rather close-knit. This is why no mat­ter how SinoMab grows in the fu­ture, pro­to­type R&D will al­ways be done here and we will on­ly go to Chi­na for the scale-up.

Those would be key sell­ing points for Hong Kong to con­tin­ue com­pet­ing with oth­er biotech hubs in Chi­na — most no­tably Shang­hai, which re­cent­ly opened up its own biotech board.

Open­ing up the stock mar­ket to biotech is go­ing to build up an en­tire biotech ecosys­tem around it. The im­pli­ca­tions go way be­yond the stock mar­ket. There will be dozens of R&D fo­cused com­pa­nies in the com­ing years as a re­sult of it.

— Brad Lon­car (@brad­lon­car) Ju­ly 8, 2019

SinoMab has ac­cu­mu­lat­ed a num­ber of Chi­nese in­vestors af­ter five ven­ture rounds. Aside from the 21.7% Le­ung holds via Skytech Tech­nol­o­gy, there are three oth­er big share­hold­ers: Forbes Cap­i­tal So­lu­tions claims 24.21%, Hainan Haiyao con­trols 18.45%, and Apri­cot has a 25.83% stake pri­or to the IPO.

So­cial im­age: Shut­ter­stock

The firehose of biopharma news is gushing these days.

That’s why broader and deeper is the theme for 2021 at Endpoints. You can expect new coverage outside our core R&D focus, with deeper reporting in some key areas. When John Carroll and I launched Endpoints nearly five years ago, we were wading in waist-high waters. Now we’re a team of 25 full-time staffers (and growing) with plans to cover the flood of biopharma news, Endpoints-style.

It’s time for a new FDA commissioner to come on board, a rite of passage for Joe Biden’s administration that should help seal the new president’s rep on seeking out the experts to lead the government over the next 4 years.

As of now, the competition for the top job appears to have narrowed down to 2 people: The longtime CDER chief Janet Woodcock and Joshua Sharfstein, the former principal deputy at the FDA under Peggy Hamburg. Both were appointed by Barack Obama.

After about four stealthy years in the development phase, San Diego-based Neuvogen is emerging with a new approach to whole-cell cancer vaccines and nine solid tumor programs bound for the clinic.

Whole-cell tumor vaccines are developed by taking cancer cells from patients and modifying them to make them immunogenic.

“What’s different from what we do, is most people use one cell line. We use six,” CEO Todd Binder said. From there, the company builds out six modifications to eliminate problematic immunosuppressive factors, and add what the executive called three “stimulatory factors” to generate a prime and overcome peripheral tolerance.